New ownership to support continued growth and innovation of leading global CDMO

COPENHAGEN, Denmark, BOSTON, Mass., and SOMERSET, N.J. Novo Holdings A/S (“Novo Holdings”), a leading global life science investor, and Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion. In connection with the transaction, Novo Holdings will sell three of Catalent’s nearly 50 global sites to Novo Nordisk A/S (“Novo Nordisk”). The three fill-finish sites that Novo Nordisk will be acquiring are located in Anagni (Italy); Bloomington (USA); and Brussels (Belgium).

Catalent is a leading partner to some of the most innovative biopharma companies in the world. Over the past 10 years, Catalent has assisted in 50% of all FDA approvals, demonstrating the strength of its industry-leading clinical supply management capabilities. The acquisition of Catalent builds on Novo Holdings’ track record of creating sustainable value creation within life sciences through its engaged ownership model. With this partnership, Catalent and Novo Holdings will continue to advance their shared mission of helping people around the world live better and healthier lives.

“Catalent helps its biopharma partners launch over 150 new products every year,” said Jonathan Levy, Senior Partner, Novo Holdings. “With our deep experience in the life sciences sector, Novo Holdings sees a significant opportunity to support Catalent’s continued commercial success, driving future growth while benefitting patients around the world.”

Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, “The completion of this transaction marks a significant milestone for Catalent. As a private company with Novo Holdings’ partnership and support, we are well-positioned to deliver better outcomes for our customers and the patients they serve, and ultimately create value for our stakeholders.”

Kasim Kutay, CEO of Novo Holdings, said, “We are pleased to welcome Alessandro and the talented Catalent team to the Novo Holdings family. Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is closely aligned with Novo Holdings’ purpose to invest for the benefit of people and the planet.”

Advisors
Morgan Stanley & Co. LLC served as financial advisor to Novo Holdings and Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Citi and J.P. Morgan served as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to Catalent and Jones Day served as legal advisor to the Catalent Board of Directors.

About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.

www.novoholdings.dk

About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.